Immunosuppressive treatment for chemotherapy-resistant multisystem langerhans cell histiocytosis

Medical and Pediatric Oncology

Volumn 40, Issue 4, 2003, Pages 253-256

  Minkov, Milen ^a   Grois, Nicole ^a   Braier, Jorge ^b   Rosso, Diego ^b   Aricò, Maurizio ^c   Broadbent, Valerie ^d   Gadner, Helmut ^a   Ladisch, Stephan ^e  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c Ospedale dei Bambini G Di Cristina   (Italy)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Antithymocyte globulin; Cyclosporin A; Immunosuppressive therapy; Langerhans cell histiocytosis

Indexed keywords

CLADRIBINE; CYCLOSPORIN A; ETOPOSIDE; INDOMETACIN; PREDNISOLONE; PREDNISONE; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; VINBLASTINE;

ALOPECIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHEMOTHERAPY; CHRONIC RESPIRATORY FAILURE; CLINICAL PROTOCOL; DIABETES INSIPIDUS; DISEASE COURSE; DONOR; FOLLOW UP; GROWTH DISORDER; HEARING LOSS; HISTIOCYTOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; IRRADIATION; LANGERHANS CELL; PARENT; PRIORITY JOURNAL; PUVA; RISK FACTOR; SALVAGE THERAPY; SCAR; SIBLING; TREATMENT FAILURE; TREATMENT OUTCOME;

CHILD, PRESCHOOL; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0037398735     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10167     Document Type: Article

References (12)

1. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 study group. Med Pediatr Oncol 1994;23:72-80.
2. Minkov M, Grois N, Heitger A, et al. Response to initial treatment: An important prognostic predictor in multisystem Langerhans cell histiocytosis. Med Pediatr Oncol (in press).
3. Komp DM, Herson J, Starling KA, et al. A staging system for histiocytosis X: A southwest oncology group study. Cancer 1981;47:798-800.
4. Ladisch S, Gartner H. Treatment of Langerhans cell histiocytosis-evolution and current approaches. Br J Cancer Suppl 1994;23:S41-S46.
5. Lahey E. Histiocytosis X: An analysis of prognostic factors. J Pediatr 1975;87:184-189.
6. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138:728-734.
7. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:327-338.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Mahmoud HH, Wang WC, Murphy SB. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood 1991;77:721-725.
10. Arico M. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Blood 1991;78:3107.
11. Stephan JL, Donadieu J, Ledeist F, et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 1993;82:2319-2323.
12. Minkov M, Grois N, Broadbent V, et al. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis. Med Pediatr Oncol 1999;33:482-485.